Tapas Guha Thakurata

#843

Chief Executive Officer

Guj. Themis Bio.·Healthcare

Age

30y

Exp

Tenure

4/10

Risk

PragmaticOutsiderSmall Cap

🎓 Graduate/Professional

🏛️ None

Company NSE

CompensationTBP

Personality

Open

Cons

Extr

Agre

Neur

Guj. Themis Bio.

Healthcare · Small Cap

High Growth · Innovation-Led

About

Tapas Guha Thakurata is the Chief Executive Officer of Guj. Themis Bio., a Small Cap company in the Healthcare sector with a market cap of ₹3K Cr. A Pragmatic leader with 30 years of experience, he is known for consensus-driven decision-making and organic builder strategy. Maintains a conservative, process-driven approach focusing on specialized pharmaceutical manufacturing within strict regulatory compliance frameworks.

FAQ

What is Tapas Guha Thakurata's leadership style?

Tapas Guha Thakurata is classified as a Pragmatic leader. He is consensus-driven in decision-making, with a shareholder champion motivation and steady-marathon pace of execution.

What is Tapas Guha Thakurata's educational background?

Tapas Guha Thakurata holds a Graduate/Professional.

Who is the CEO of Guj. Themis Bio.?

Tapas Guha Thakurata is the Chief Executive Officer of Guj. Themis Bio.. He has been with the company for 3 years and in the current role for 3 years.

Leadership DNA

ArchetypePragmatic

MotivationShareholder Champion

CrisisSteady Hand

DecisionConsensus-Driven

GrowthOrganic Builder

PeopleNumbers Driven

InnovationFast-Follower

PaceSteady-Marathon

PurposePurpose-Blended

CustomerB2B-Enterprise

EmployerSteady Employer

BrandTechnical-Expert

FocusOperational Excellence

OrientationDeep Specialist

Leadership Evidence

“Maintains a conservative, process-driven approach focusing on specialized pharmaceutical manufacturing within strict regulatory compliance frameworks.”

⚡ Crisis●●●○○

His leadership at Gujarat Themis BioSyn has been characterized by consistent operational stability and steady capacity utilization rather than radical pivots or aggressive cost-cutting.

🎯 Motivation●●●○○

Under his tenure, the company has focused on consistent margin improvement and profitability, resulting in significant value creation for public shareholders.

👥 People●●●○○

The operational turnaround of the company was achieved through a rigorous focus on manufacturing efficiency, yield optimization, and strict adherence to production KPIs.

📈 Growth●●●●○

Growth has been driven primarily by expanding the existing API manufacturing capacity and improving operational efficiencies at the Vapi facility.

💡 Innovation●●●●○

The company focuses on niche therapeutic segments like anti-TB and anti-malarial drugs by leveraging established generic formulations and process chemistry.

🏃 Pace●●●●○

The company maintains a consistent operational rhythm focused on incremental capacity expansion and steady regulatory compliance rather than aggressive, high-frequency product disruption.

🌱 Purpose●●●○○

As a key player in essential medicine segments like anti-tuberculosis, their business model inherently aligns with public health mandates and government-led healthcare initiatives.

🏷️ Brand●●●●○

The company is recognized for its technical proficiency in manufacturing complex niche formulations rather than consumer-facing brand building.

🤝 Customer●●●●○

The business operates primarily as a manufacturer and supplier of specialty pharmaceuticals to hospitals, government institutions, and larger distribution networks.

💼 Employer●●●○○

As a specialized mid-to-small cap pharmaceutical manufacturer, the company offers a stable, process-oriented environment typical of established manufacturing-led pharma firms.

📋 Mandate

Requires heavy R&D focus and intellectual property development to scale its niche pharmaceutical offerings and compete globally.

🏢 Culture●●●○○

Operating in specialty pharma with a focus on high-growth niche therapeutic areas necessitates an R&D-centric, experimentation-oriented work environment.